It is anticipated that FcRn blockade might be beneficial for a subgroup of CIDP patients, targeting pathophysiologically relevant IgGs and enabling a more individually tailored treatment strategy. The gene discussed is FCGRT; the disease is chronic inflammatory demyelinating polyradiculoneuropathy.